马上注册，阅读更多内容，享用更多功能！
您需要 登录 才可以下载或查看，没有账号？立即注册 
×
长效奥曲肽
长效奥曲肽， 20~30mg， 肌内注射/深部肌肉注射， 第 1 天， 28 天 1 个周期
兰瑞肽
兰瑞肽， 120mg， 皮下注射， 第 1 天， 28 天 1 个周期
兰瑞肽
兰瑞肽， 40mg， 肌肉注射， 第 1 天， 每14 天 1 个周期
PRRT疗法（Peptide Receptor- Radionuclide Therapy肽受体-放射性核素治疗）
PRRT 200mCi（1mCi=3.7×107Bq） 静脉注射 第 1 天 每 8 周重复，共 4 次
索凡替尼
索凡替尼，300mg，口服，每天一次
舒尼替尼
舒尼替尼 37.5mg，口服，每天一次
依维莫司
依维莫司 10mg，口服，每日 1 次。
基于经验，CSCO 指南建议5mg，口服，每天1次为起始剂量
CAPTEM 方案
卡培他滨 750mg/m2 口服 第 1~14 天 每日 2 次
替莫唑胺 200mg/m2 口服 第 10~14 天 每日 1 次
每 4 周重复（注意两种药物的服药顺序）
EP 方案1
依托泊苷 100mg/m2 静脉输注 第 1~3 天
顺铂 75mg/m2 静脉输注 第 1 天
每 3 周重复，共 4~6 个周期
EP 方案2
依托泊苷 80mg/m2 静脉输注 第 1~3 天
顺铂 80mg/m2 静脉输注 第 1 天
每 3 周重复，共 4~6 个周期
EP 方案3
依托泊苷 100mg/m2 静脉输注 第 1~3 天
顺铂 25mg/m2 静脉输注 第 1~3 天
每 3 周重复，共 4~6 个周期
EC 方案
依托泊苷 100mg/m2 静脉输注 第 1~3 天
卡铂 AUC=5 静脉输注 第 1 天
每 3 周重复，共 4~6 个周期
依托泊苷单药
依托泊苷 50mg，口服，每天一次，第 1~10 天
每 3 周重复，治疗2~3周期复查
IP 方案1
伊立替康 60mg/m2 静脉输注 第 1、8、15天
顺铂 60mg/m2 静脉输注 第 1 天
每 4 周重复，共 4~6 个周期
IP 方案2
伊立替康 65mg/m2 静脉输注 第 1、8天
顺铂 30mg/m2 静脉输注 第 1 、8天
每 3 周重复，共 4~6 个周期
mFOLFOX6方案
奥沙利铂 85mg/m2 静脉输注2h 第 1 天
LV 400mg/m2，静脉输液2h，第1天
5-FU 400mg/m2，静脉推注，第1天；然后 1200mg/(m2·d)×2d，持续静脉输液（总量 2400mg/m2，输液46-48h）
每 2 周重复（请注意，这里没有写明周期数）
CAPOX方案
奥沙利铂 130mg/m2 静脉输注大于2h 第 1 天
卡培他滨 1000mg/m2，口服，每天2次，第1-14天
每 3 周重复（请注意，这里没有写明周期数）
更新：20240831
参考指南：
- 中国临床肿瘤学会指南工作委员会.中国临床肿瘤学会 (CSCO) 小细胞肺癌诊疗指南2024.人民卫生出版社.北京 2024
- 中国临床肿瘤学会指南工作委员会.中国临床肿瘤学会 (CSCO) 神经内分泌肿瘤诊疗指南2022.人民卫生出版社.北京 2022
参考文献
［1］ HONG CR, WIRTH LJ, NISHINO M, et al. Chemotherapy for locally advanced and metastatic pulmonary carcinoid tumors. Lung Cancer, 2014, 86 (2): 241-246.
［2］ WIRTH LJ, CARTER MR, JÄNNE PA, et al. Outcome of patients with pulmonary carcinoid tumors receiving chemo- therapy or chemoradiotherapy. Lung Cancer, 2004, 44 (2): 213-220.
［3］ FILOSSO PL, YAO X, AHMAD U, et al. Outcome of primary neuroendocrine tumors of the thymus: A joint analysis of the International Thymic Malignancy Interest Group and the European Society of Thoracic Surgeons databases. J Thorac Cardiovasc Surg, 2015, 149 (1): 103-109.
［4］ RIMNER A, YAO X, HUANG J, et al. Postoperative radiation therapy is associated with longeroverall survival in completely resected stage Ⅱ and Ⅲ thymoma-an analysis of the international thymic malignancies interest group ret- rospective database. J Thorac Oncol, 2016, 11 (10): 1785-1792.
［5］ BIAN D, QI M, HU J, et al. The comparison of predictive factors regarding prognoses and invasion of thymic neuro- endocrine tumors preoperatively and postoperatively. J Thorac Dis, 2018, 10 (3): 1657-1669.
［6］ CRONA J, FANOLA I, LINDHOLM DP, et al. Effect of temozolomide in patients with metastatic bronchial carci- noids. Neuroendocrinology, 2013, 98 (2): 151-155.
［7］ PAULSON AS, BERGSLAND EK. Systemic therapy for advanced carcinoid tumors: Where do we go from here?. J Natl Compr Canc Netw, 2012, 10 (6): 785-793.
［8］ MEDLEY L, MOREL AN, FARRUGIA D, et al. Phase Ⅱ study of single agent capecitabine in the treatment of meta- static non-pancreatic neuroendocrine tumours. Br J Cancer, 2011, 104 (7): 1067-1070.
［9］ BAJETTA E, CATENA L, PROCOPIO G, et al. Are capecitabine and oxaliplatin (XELOX) suitable treatments for pro- gressing low-grade and high-grade neuroendocrine tumours?. Cancer Chemother Pharmacol, 2007, 59 (5): 637-642.
［10］ EKEBLAD S, SUNDIN A, JANSON ET, et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res, 2007, 13 (10): 2986-2991.
［11］ CRONA J, FANOLA I, LINDHOLM DP, et al. Effect of temozolomide in patients with metastatic bronchial carci- noids. Neuroendocrinology, 2013, 98 (2): 151-155.
［12］ YAO JC, PHAN AT, CHANG DZ, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low-to intermediate-grade neuroendocrine tumors: Results of a phase Ⅱ study. J Clin Oncol, 2008, 26 (26): 4311-4318.
［13］ PAVEL ME, HAINSWORTH JD, BAUDIN E, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): A randomised, placebo-controlled, phase 3 study. Lancet, 2011, 378 (9808): 2005-2012.
［14］ YAO JC, FAZIO N, SINGH S, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): A randomised, placebo-controlled, phase 3 study. Lan- cet, 2016, 387 (10022): 968-977.
［15］ FAZIO N, BUZZONI R, DELLE FAVE G, et al. Everolimus in advanced, progressive, well-differentiated, non- functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis. Cancer Sci, 2018, 109 (1): 174-181.
［16］ IMHOF A, BRUNNER P, MARINCEK N, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol, 2011, 29 (17): 2416-2423.
［17］ KRENNING EP, TEUNISSEN JJ, VALKEMA R, et al. Molecular radiotherapy with somatostatin analogs for (neuro-) endocrine tumors. J Endocrinol Invest, 2005, 28 (11 Suppl International): 146-150.
［18］ KWEKKEBOOM DJ, BAKKER WH, KAM BL, et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA (0), Tyr3] octreotate. Eur J Nucl Med Mol Imaging, 2003, 30 (3): 417-422.
［19］ KWEKKEBOOM DJ, TEUNISSEN JJ, BAKKER WH, et al. Radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3] octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol, 2005, 23 (12): 2754-2762.
［20］ KWEKKEBOOM DJ, TEUNISSEN JJ, KAM BL, et al. Treatment of patients who have endocrine gastroenteropan- creatic tumors with radiolabeled somatostatin analogues. Hematol Oncol Clin North Am, 2007, 21 (3): 561-573.
［21］ BUSHNELL DL JR, O′DORISIO TM, O′DORISIO MS, et al. 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol, 2010, 28 (10): 1652-1659.
［22］ KONG G, THOMPSON M, COLLINS M, et al. Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT). Eur J Nucl Med Mol Imaging, 2014, 41 (10): 1831-1844.
［23］ VILLARD L, ROMER A, MARINCEK N, et al. Cohort study of somatostatin-based radiopeptide therapy with [(90) Y-DOTA]-TOC versus [(90) Y-DOTA]-TOC plus [(177) Lu-DOTA]-TOC in neuroendocrine cancers. J Clin Oncol, 2012, 30 (10): 1100-1106.
［24］ HÖRSCH D, EZZIDDIN S, HAUG A, et al. Peptide receptor radionuclide therapy for neuroendocrine tumors in Germany: First results of a multi-institutional cancer registry. Recent Results Cancer Res, 2013, 194: 457-465.
［25］ BRABANDER T, VAN DER ZWAN WA, TEUNISSEN J, et al. Long-term efficacy, survival, and safety of [177Lu- DOTA0, Tyr3] octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clin Cancer Res, 2017, 23 (16): 4617-4624.
［26］ U. S. Food and Drug Administration. FDA approves new treatment for certain digestive tract cancers. Silver Springs, MD: U. S. Food and Drug Administration.(2018-01-16)[2024-03-25]. https://www. fda. gov/news-events/press- announcements/fda-approves-new-treatment-certain-digestive-tract-cancers.
［27］ CAPDEVILA J, HERNANDO J, TEULE A, et al. Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin. Nature Communications, 2023, 14: 2973.
［28］ GRAND B, CAZES A, MORDANT P, et al. High grade neuroendocrine lung tumors: Pathological characteristics, surgical management and prognostic implications. Lung Cancer, 2013, 81 (3): 404-409.
［29］ SAJI H, TSUBOI M, MATSUBAYASHI J, et al. Clinical response of large cell neuroendocrine carcinoma of the lung to perioperative adjuvant chemotherapy. Anticancer Drugs, 2010, 21 (1): 89-93.
［30］ KENMOTSU H, NIHO S, ITO T, et al. A pilot study of adjuvant chemotherapy with irinotecan and cisplatin for completely resected high-grade pulmonary neuroendocrine carcinoma (large cell neuroendocrine carcinoma and small cell lung cancer). Lung Cancer, 2014, 84 (3): 254-258.
［31］ GRIDELLI C, ROSSI A, AIROMA G, et al. Treatment of pulmonary neuroendocrine tumours: State of the art and future developments. Cancer Treat Rev, 2013, 39 (5): 466-472.
［32］ LO RUSSO G, PUSCEDDU S, PROTO C, et al. Treatment of lung large cell neuroendocrine carcinoma. Tumour Biol, 2016, 37 (6): 7047-7057.
［33］ LIMONNIK V, ABEL S, FINLEY GG, et al. Factors associated with treatment receipt and overall survival for patients with locally advanced large cell neuroendocrine carcinoma of the lung: A National Cancer Database analy- sis. Lung Cancer, 2020, 150: 107-113.
［34］ DERKS JL, LEBLAY N, THUNNISSEN E, et al. Molecular subtypes of pulmonary large-cell neuroendocrine carci- noma predict chemotherapy treatment outcome. Clin Cancer Res, 2018, 24 (1): 33-42.
［35］ LEVRA MG, MAZIERES J, VALETTE CA, et al. P1. 07-012 efficacy of immune checkpoint inhibitors in large cell neuroendocrine lung cancer: Results from a french retrospective cohort. Topic: drug treatment alone and in combina- tion with radiotherapy. J Thoracic Oncol, 2017, 12 (1): S702-S703.
［36］ WANG VE, URISMAN A, ALBACKER L, et al. Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden. J Immunother Cancer, 2017, 5 (1): 75.
|
|
